Related references
Note: Only part of the references are listed.Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Richard S. Finkel et al.
LANCET (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study
Stephen J. Kolb et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Survival Motor Neuron (SMN) protein is required for normal mouse liver development
Eva Szunyogova et al.
SCIENTIFIC REPORTS (2016)
Moving towards treatments for spinal muscular atrophy: hopes and limits
Brunhilde Wirth et al.
EXPERT OPINION ON EMERGING DRUGS (2015)
Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models
Yimin Hua et al.
GENES & DEVELOPMENT (2015)
SPINAL MUSCULAR ATROPHY: DIAGNOSIS AND MANAGEMENT IN A NEW THERAPEUTIC ERA
W. David Arnold et al.
MUSCLE & NERVE (2015)
Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?
Monir Shababi et al.
JOURNAL OF ANATOMY (2014)
SMA VALIANT TRIAL: A PROSPECTIVE, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF VALPROIC ACID IN AMBULATORY ADULTS WITH SPINAL MUSCULAR ATROPHY
John T. Kissel et al.
MUSCLE & NERVE (2014)
Observational study of spinal muscular atrophy type I and implications for clinical trials
Richard S. Finkel et al.
NEUROLOGY (2014)
Reliability and Validity of the TIMPSI for Infants With Spinal Muscular Atrophy Type I
Kristin J. Krosschell et al.
PEDIATRIC PHYSICAL THERAPY (2013)
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model
Yimin Hua et al.
NATURE (2011)
SMA CARNI-VAL TRIAL PART II: A Prospective, Single-Armed Trial of L-Carnitine and Valproic Acid in Ambulatory Children with Spinal Muscular Atrophy
John T. Kissel et al.
PLOS ONE (2011)
Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice
Christopher R. Heier et al.
HUMAN MOLECULAR GENETICS (2010)
Cardiac defects contribute to the pathology of spinal muscular atrophy models
Monir Shababi et al.
HUMAN MOLECULAR GENETICS (2010)
Early heart failure in the SMNΔ7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery
Adam K. Bevan et al.
HUMAN MOLECULAR GENETICS (2010)
SMA CARNI-VAL Trial Part I: Double-Blind, Randomized, Placebo-Controlled Trial of L-Carnitine and Valproic Acid in Spinal Muscular Atrophy
Kathryn J. Swoboda et al.
PLOS ONE (2010)
Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy
Kathryn J. Swoboda et al.
PLOS ONE (2009)
Validity of the TIMPSI for Estimating Concurrent Performance on the Test of Infant Motor Performance
Suzann K. Campbell et al.
Pediatric Physical Therapy (2009)
Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice
Li-Kai Tsai et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2008)
Valproic acid treatment in six patients with spinal muscular atrophy
L. -K. Tsai et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
Establishing a standardized therapeutic testing protocol for spinal muscular atrophy
Li-Kai Tsai et al.
NEUROBIOLOGY OF DISEASE (2006)
Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy
Conrad C. Weihl et al.
NEUROLOGY (2006)
Endogenous α-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity
Yan Leng et al.
JOURNAL OF NEUROSCIENCE (2006)
In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate
Lars Brichta et al.
ANNALS OF NEUROLOGY (2006)
Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number
B Wirth et al.
HUMAN GENETICS (2006)
Valproic acid promotes neurite outgrowth in PC12 cells independent from regulation of the survival of motoneuron protein
J van Bergeijk et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2006)
Natural history of denervation in SMA:: Relation to age, SMN2 copy number, and function
KJ Swoboda et al.
ANNALS OF NEUROLOGY (2005)
Benefit of valproic acid in suppressing disease progression of ALS model mice
F Sugai et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2004)
Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy
L Brichta et al.
HUMAN MOLECULAR GENETICS (2003)
Valproic acid increases SMN levels in spinal muscular atrophy patient cells
CJ Sumner et al.
ANNALS OF NEUROLOGY (2003)
Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR:: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy
M Feldkötter et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2
MD Mailman et al.
GENETICS IN MEDICINE (2002)
Share Paper
